checkAd
    Startseite > Aktien > Exelixis > Nachrichten
    Exelixis Aktie
    20,910
     
    USD
    -1,51 %
    -0,320 USD
    Letzter Kurs 18.05.24 Nasdaq
    20,910
     
    USD
    200 STK
    Geldkurs 17.05.24
    20,920
     
    USD
    4.600 STK
    Briefkurs 17.05.24
    ISIN: US30161Q1040 · WKN: 936718 · SYM: EXEL · USA

    Neueste Nachrichten

    Exelixis to Webcast Fireside Chats as Part of Investor Conferences in May
    07.05.24 · Business Wire (engl.) · Exelixis
    Exelixis Announces First Quarter 2024 Financial Results and Provides Corporate Update
    30.04.24 · Business Wire (engl.) · Exelixis
    Exelixis to Release First Quarter 2024 Financial Results on Tuesday, April 30, 2024
    16.04.24 · Business Wire (engl.) · Exelixis
    Fokus Aktien mit extremen Handelsvolumen am Montag, den 01.04.2024
    01.04.24 · wO Chartvergleich · Consolidated Water
    Fokus Aktien mit extremen Handelsvolumen am Freitag, den 29.03.2024
    29.03.24 · wO Chartvergleich · Consolidated Water
    Fokus Aktien mit extremen Handelsvolumen am Donnerstag, den 28.03.2024
    28.03.24 · wO Chartvergleich · Energiekontor
    Exelixis to Webcast Fireside Chats as Part of Investor Conferences in March
    27.02.24 · Business Wire (engl.) · Exelixis
    Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update
    06.02.24 · Business Wire (engl.) · Exelixis
    Exelixis to Webcast Fireside Chats as Part of Investor Conferences in February
    01.02.24 · Business Wire (engl.) · Exelixis
    Exelixis Announces Detailed Results of Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer Presented at ASCO GU 2024
    25.01.24 · Business Wire (engl.) · Exelixis
    Exelixis to Release Fourth Quarter and Fiscal Year 2023 Financial Results on Tuesday, February 6, 2024
    23.01.24 · Business Wire (engl.) · Exelixis
    Opdivo (nivolumab) in Combination with CABOMETYX (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
    22.01.24 · Business Wire (engl.) · Bristol-Myers Squibb